IMPROVE THE QUALITY OF CLINICAL DIAGNOSTICS WITH TARGETED PRODUCT INNOVATIONS



GIULIANO BARBARO, R&D DIRECTOR OF IMAGING DEVICES





of any Revenio Group Corporations' shares.

independent financial adviser.

estimates may change in the event of significant changes in general economic conditions.

Disclaimer

- This presentation does not constitute an invitation to underwrite, subscribe for, or otherwise acquire or dispose
- Group's past performance is no guide to future performance, and persons needing advice should consult an
- This presentation contains statements that are estimates based on the management's best knowledge at the time they were made. For this reason, they involve a certain amount of inherent risk and uncertainty. The







We focus on sight-threatening pathologies The most prevalent ophthalmic disorders are age related

Glaucoma

- 80 million detected
- 50 % undetected
- Leading cause of preventable blindness
- Clinical management requires tonometry, fundus imaging and perimetry

Diabetic Retinopathy

- Global prevalence of ulletdiabetes among adults risen from 4.7% in 1980 to 8.5% in 2014
- Detected and monitored by means of fundus imaging





DAY 2021

Age-related Macular Degeneration

- 196 million global ulletprojected cases in 2020, rising to 288 million in 2040
- Clinically detected and ulletmonitored with fundus imaging and OCT

Glaucoma, diabetic retinopathy, and age-related macular degeneration collectively led to more than 19 million cases of vision impairment in adults aged 50+ years in 2020, making these diseases important targets for prevention and treatment"

The Lancet Global Health 2021











Improve the quality of clinical diagnostics with targeted product innovations

Tonometry

Rebound tonometry

Home tonometry

Fundus Imaging

True-color confocal imaging Fully automated capture







DAY 2021

Perimetry

Fundus imaging & automated perimetry in one device

Future products & product enhancements











DAY 2021



Make rebound technology the clinical standard for tonometry





Highest accuracy and repeatability

Safe for patients, due to the disposable probes

Fast measurement

Highest patient comfort

Ease of use, minimal training

Compact size



Make true-color confocal fundus imaging the clinical standard



DAY 2021



In 2010, we were the first to introduce fully automated image acquisition



Auto-alignment



Auto-focus



Auto-exposure



Auto-capture

DAY 2021

Full automation:

- delivers consistent-quality images ullet
- greatly enhances ease of use
- frees doctors from spending time with machines ullet
- makes screening accessible to enable ulletprevention





In 2014, we were first to introduce true-color confocal imaging

Our technology:

Improves image resolution and visibility of details

Provides color fidelity

Augments information content

Eliminates need for pupil dilation









In 2014, we were first to introduce true-color confocal imaging

Our technology:

Improves image resolution and visibility of details

Provides color fidelity

Augments information content

Eliminates need for pupil dilation



Make true-color confocal the standard in fundus imaging

Overall, true-color confocal imaging combined with fully automated acquisition:	Al perforn 3 rd party's
Increase accessibility of imaging	100% 94,7 90%
Enhance clinical accuracy	80% 70%
Maximize performance of autonomous AI solutions	60% 50%
	40% 30%
	20%
	0%

DAY 2021

mance for autonomous detection of Diabetic Retinopathy: Al using Eidon images vs. fundus camera

Make fundus perimetry a standard in the management of glaucoma

Perimetry is a measurement used to detect disfunctions in the visual field.

DAY 2021

Make fundus perimetry a standard in the management of glaucoma

Our technology:

Improves accuracy of the measurement by compensating eye movements

Provides a combined assessment of the anatomy and function of the retina

Offers unique capabilities for stereoscopic imaging of the optic nerve

Expand product portfolio both organically and inorganically

Organic expansion

is envisioned both in posterior segment (retina) as well as in anterior segment (ocular surface and anterior chamber) diagnostic

DAY 2021

Inorganic expansion

is sought by exploring OEM and acquisition opportunities targeting products that are complementary to the existing portfolio

iCare HOME2 – Easy and accurate IOP self-measurement

Unsurpassed ease of use and accuracy in monitoring real-world IOP behavior

Most patients can take iCare HOME2 into use simply by following the advice in the training materials.

iCare HOME2 guides the patient to always make a high-quality measurement.

iCare HOME2 – Glaucoma management based on real-life IOP information

Optimizing treatment plan

Assessing need for and effectiveness of surgery

Improving patients' compliance to medication

DAY 2021

Assess future innovation opportunities through clinical research

We are supporting clinical research in the following areas of imaging where we have developed innovative solutions:

Metabolic retinal imaging using novel auto-fluorescence methods

Retinal imaging to detect signs of Alzheimer's disease

Improve the quality of clinical diagnostics with targeted product innovations

Make rebound technology the clinical standard for tonometry

Make true-color confocal • imaging the standard in fundus imaging

Make fundus perimetry a standard in the management of glaucoma

Key takeaways

Assess future innovation opportunities through research

Expand product portfolio both organically and inorganically

We aspire to keep the wonderful world visible for all with following key strategic cornerstones

fully on the eye care market

Improve

the quality of clinical diagnostics with targeted product innovations

clinical care pathways with eye care focused software solutions

Transform

Build

on iCare brand awareness and customer experience

Continue

strong profitable growth

"WE ASPIRE TO KEEP THE WONDERFUL WORLD VISIBLE FOR ALL"

Thank you! Questions?

